About geron - GERN
Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.
GERN At a Glance
Geron Corp.
919 East Hillsdale Boulevard
Foster City, California 94404
| Phone | 1-650-473-7700 | Revenue | 183.88M | |
| Industry | Biotechnology | Net Income | -83,500,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 138.825% | |
| Fiscal Year-end | 12 / 2026 | Employees | 258 | |
| View SEC Filings |
GERN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 4.786 |
| Price to Book Ratio | 3.739 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -15.328 |
| Enterprise Value to Sales | 4.197 |
| Total Debt to Enterprise Value | 0.326 |
GERN Efficiency
| Revenue/Employee | 712,717.054 |
| Income Per Employee | -323,643.411 |
| Receivables Turnover | 4.688 |
| Total Asset Turnover | 0.316 |
GERN Liquidity
| Current Ratio | 4.664 |
| Quick Ratio | 3.619 |
| Cash Ratio | 3.226 |
GERN Profitability
| Gross Margin | 97.42 |
| Operating Margin | -28.036 |
| Pretax Margin | -45.41 |
| Net Margin | -45.41 |
| Return on Assets | -14.328 |
| Return on Equity | -32.991 |
| Return on Total Capital | -17.489 |
| Return on Invested Capital | -17.315 |
GERN Capital Structure
| Total Debt to Total Equity | 111.379 |
| Total Debt to Total Capital | 52.692 |
| Total Debt to Total Assets | 44.052 |
| Long-Term Debt to Equity | 103.212 |
| Long-Term Debt to Total Capital | 48.828 |